Perrigo (PRGO) Cash from Financing Activities (2013 - 2026)

Perrigo's (PRGO) quarterly Cash from Financing Activities came in at -$45.3 million in Q1 2026, up 26.7% year-on-year from -$35.8 million in Q1 2025, and up 16.73% on a QoQ basis from -$54.4 million in Q4 2025.

Perrigo (PRGO) Cash from Financing Activities (2013 - 2026) Analysis & Trends

Perrigo (PRGO) has 14 years of Cash from Financing Activities data on file, last reported at -$45.3 million in Q1 2026.

  • On a quarterly basis, Cash from Financing Activities rose 26.7% year-over-year to -$45.3 million in Q1 2026; TTM through Mar 2026 was -$204.0 million, a 66.69% increase from a year earlier, with the FY2025 full-year figure at -$220.5 million, up 63.91% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at -$45.3 million, up from -$54.4 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for PRGO reached as high as $653.3 million in Q3 2024 and fell as low as -$1.2 billion in Q4 2024.
  • Historically, Cash from Financing Activities has averaged -$37.8 million across 5 years, with a median of -$49.8 million in 2024.
  • On a YoY basis, Cash from Financing Activities climbed as much as 1608.78% in 2024 and fell as far as 2487.67% in 2024.
  • Year by year, Cash from Financing Activities stood at -$42.5 million in 2022, then dropped by 4.94% to -$44.6 million in 2023, then plunged by 2487.67% to -$1.2 billion in 2024, then surged by 95.29% to -$54.4 million in 2025, then advanced by 16.73% to -$45.3 million in 2026.
  • Per Business Quant data, the three most recent Cash from Financing Activities figures were -$45.3 million in Q1 2026, -$54.4 million in Q4 2025, and -$50.3 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 13.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -840.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -494.13 Mn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -1.48 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -203.80 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -86.10 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -65.00 Mn
10 Perrigo 1.40 Bn 1.05 Bn 325.50 Mn -45.30 Mn

Historic Data

Download Data
DateValue
Mar 28, 2026 -45.30 Mn
Mar 28, 2026 -45.30 Mn
Dec 31, 2025 -54.40 Mn
Dec 31, 2025 -54.40 Mn
Sep 27, 2025 -50.30 Mn
Sep 27, 2025 -50.30 Mn
Jun 28, 2025 -54.00 Mn
Jun 28, 2025 -54.00 Mn
Mar 29, 2025 -61.80 Mn
Mar 29, 2025 -61.80 Mn
Dec 31, 2024 -1.15 Bn
Dec 31, 2024 -1.15 Bn
Sep 28, 2024 653.30 Mn
Sep 28, 2024 653.30 Mn
Jun 29, 2024 -49.80 Mn
Jun 29, 2024 -49.80 Mn
Mar 30, 2024 -60.40 Mn
Mar 30, 2024 -60.40 Mn
Dec 31, 2023 -44.60 Mn
Dec 31, 2023 -44.60 Mn